Related Experiment Video
Updated: Apr 19, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
Published on: June 5, 2015
[Immunoglobulin therapy]
Insights
Kawasaki disease (KD) is an acute vasculitis affecting children. Intravenous immunoglobulin (IVIG) treats KD, but some patients are resistant, necessitating further research into IVIG mechanisms and alternative therapies.
Area of Science:
- Pediatric rheumatology
- Immunology
- Vascular biology
Context:
- Kawasaki disease (KD) is an acute, self-limited vasculitis affecting primarily infants and children.
- Coronary artery (CA) aneurysms are a severe complication, occurring in 25% of untreated children.
- Intravenous immunoglobulin (IVIG) is the standard treatment, reducing CA aneurysm incidence.
Purpose:
- To review the clinical utility of IVIG in Kawasaki disease.
- To describe the proposed mechanisms of IVIG's anti-inflammatory activity in KD.
- To highlight the challenges and implications of IVIG resistance in KD patients.
Summary:
- KD is an acute vasculitis with potential for severe coronary artery (CA) complications.
- IVIG is effective in most KD cases, reducing CA aneurysms.
- 10-20% of KD patients exhibit IVIG resistance, posing a higher risk for CA abnormalities.
Impact:
- Understanding IVIG mechanisms can optimize KD treatment strategies.
- Identifying mechanisms of IVIG resistance may lead to improved therapies for non-responders.
- This review provides insights into managing KD and preventing its severe cardiovascular sequelae.
Abstract:
Kawasaki disease(KD) is an acute, self-limited vasculitis of unknown etiology that predominantly affects infants and children. Coronary artery(CA) aneurysms, the most severe complication, occur in 25 % of untreated children and may lead to ischemic heart disease, myocardial infarction, or sudden death. While a single high dose of intravenous immunoglobulin (IVIG) terminates the fever and acute inflammation in most subjects and dramatically reduces the incidence of CA aneurysms, 10 to 20 % of KD patients are IVIG- resistant and these subjects are at higher risk of developing CA abnormalities. Several mechanisms have been reported for the anti-inflammatory activity of IVIG in different disease states. In this review, we describe the clinical utility and these mechanisms of IVIG in KD.
Related Concept Videos
Tumor Immunotherapy
Humoral Immune Responses
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
Immunoprecipitation
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

